Skip to content

Abivax S.A.

US · ABVX #1658 by market cap Listed 2023
73.20 -7.45 -9.24%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

About Abivax S.A.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Founded
2003
CEO
Mr. Marc de Garidel
Employees
69
Headquarters
Paris, Ile-de-France, France
Fiscal year end
12-31
Website
abivax.com

Company profile

Exchange
US
Symbol
ABVX
Market-cap rank
#1658
Listing date
2023-10-20
Market cap
6.41B
Float cap
5.69B
Shares out
87.54M
Float shares
77.74M

Sectors & themes

Biotechnology Stocks tradable only on moomoo Fractional Shares JP

Browse all sectors & themes

Quote time 2026-11-20 20:02:37 · For reference only, not investment advice and not tailored to your situation.

Abivax S.A. discussion 0 comments

Add a comment